Mahendru Psychiatric Centre

Home Our Doctors Treatment Contact Us
 

COMPLETED CLINICAL TRIALS

 S.No.   Indication Phase   Year    Study  Duration   No. Pt.
 Screened
  No. of Pt.  Randomized   Rating Scales
  Used
 1 Bipolar-1-disorder III 2005-08 52 Weeks   120 118
YMRS, PANSS, SAS, BARS, AIMS, HAM-D, CGI-I, CGI-S


  2 Depression IV 2005-07 26 Weeks           70 
HAMD-17, MADRS, CGI-I, CGI-S, CGI-I, CGI-S


  3 Schizophrenia IV 2005-08 52 Weeks           80  Safety Outcome Study


  4 Schizophrenia III 2006-07 26 Weeks   17   15
ESRS, PANSS, CGI-I, CGI-S, SDS, M.I.N.I, RDQ


  5 Major Depressive Disorder II 2007-08 10 Weeks    15    14 HAMD-17,MADRS,CGI-I,CGI-S,M.I.N.I,RDQ


  6 Schizophrenia in adolescents II 2007-08 26 Weeks    5    3 PANSS,BARS,AIMS,SAS


  7 Acute Mania III 2007-08 6 Weeks   18   15
YMRS,MADRS,CGI-I,CGI-S,HAMD-17,SAS,BARS,AIMS


8 Major Depressive Disorder II 2007-08 6 Weeks 20 15
HAMD-17, HAMD-21, MPS, CGI-I, QIDS-SR, SF-36, BSI, HAMA, OAS-M, ASEX, ISI, FSS, M.I.N.I, YMRS


9 Schizoaffective III 2007-08 6 Weeks 14 12
PANSS, CGI-S-SA,ISST,SUMD, AIMS, SAS, HAMD-21, YMRS


10 Schizoaffective III 2007-08 6 Weeks 9 8
PANSS, CGI-S-SA,ISST,SUMD, AIMS, SAS, HAMD-21, YMRS


11 Acute Mania II 2008-08 6 Weeks 23 16
SCID, PANSS, CGI-S, CGI-I,  AIMS, SAS, MADRS, BARS


12 Schizophrenia IV 2006 104 Weeks 20 20
ESRS, PANSS,CGI, PSP, SF-36, ISST, SUMD, Cognitive Battery


13 Alzheimer's Disease III 2007 26 Weeks 15 12
MMSE, CES-D,CSDD, SIB,CIBIS,CIBIC,ADCS ADL, QoL AD, EQ 5D,SCB,TES,TOS,GATs,


14 Schizophrenia IIb 2008 6 Weeks 39 38 PANSS,CDSS,CGI-S,CGI-I, ESRS, RDQ, MODIFIED ISST, M.I.N.I PLUS,MSQ, LOF, BACs.


15 Schizophrenia IIb 2008 6 Weeks   29 25  SCID, SCI-PANSS, CGI-S, CGI-I, NSA 16, BARS, SAS, AIMS


16 Major Depressive Disorder II 2008 18 Weeks   25 11* HAMD 17, QIDS, CGI-S, CGI-I, MADRA,SDS, STS, SIS, M.I.N.I


17 Alzheimer's Disease IV 2008 52 Weeks       4  MMSE, SIB, CIBIS, CIBIC, ADCS ADL, QoL-AD, EQ 5D, SCB, TES, TOS, GATs,


18 Schizophrenia IIb 2009 6 Weeks     19  PANSS, CDSS, CGI-S, CGI-I, ESRS, RDQ, MODIFIED ISST, MSQ, LOF,BACs.


19 Schizophrenia III 2009 52 Weeks   10 3** PANSS, CDSS, CGI-S, CGI-I, S-QoL, DAI, GAF, PSP, CSRI, AIMS, BARS, SAS


 

      In This Section

* Study was to asses efficacy of augmenting agent with SSRI. Only partial responders in open label phase were randomized into double blind phase of study. The responder groups and non-responder groups were not eligible for randomization.

** Study was terminated by sponsors at all sites soon after initiation.